

Inventors: Huse and Glaser
Serial No.: 09/016,061
Filed: January 30, 1998
Page 2

Group II: claims 98-104, directed to methods of inhibiting the function of $\alpha_v\beta_3$ and of treating an $\alpha_v\beta_3$ -mediated disease with $\alpha_v\beta_3$ -specific antibodies.

Election of one of the inventions is required under 35 U.S.C. § 121. Applicants elect the claims set forth in Group I, claims 56-97, for examination. Furthermore, Applicants elect the species of antibody designated 6H6, which comprises CDRs having at least one amino acid substitution in one or more CDRs and referenced as SEQ ID NOS:90 and 94. In regard to the request to indicate which claims are readable on the elected species, Applicants submit that the elected species reads on claims 56-59, 62, 65-68, 70-77, 84, 85, 90, 91, and 94-97.


In regard to the request to point out which $\alpha_v\beta_3$ -specific antibody species or sequences comprise amino acid substitutions that are considered free of the prior art, Applicants respectfully submit that all of the claims are considered to be free of the prior art. Applicants point out that the elected claims are directed to antibodies having at least one amino acid substitution in one or more CDRs of a LM609 grafted antibody, which Applicants believe are novel and unobvious over any known prior art.

Inventors: Huse and Glaser
Serial No.: 09/016,061
Filed: January 30, 1998
Page 3

Applicants elect the claims of Group I, claims 56-97, for examination and the species of antibody designated 6H6, which comprises CDRs referenced as SEQ ID NOS:90 and 94. The Examiner is invited to call the undersigned agent or Cathryn Campbell if there are any questions.

Respectfully submitted,

Date: April 24, 2000



Deborah L. Cadena
Registration No. 44,048
Telephone No.: (858) 535-9001
Facsimile No.: (858) 535-8949

CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122